A Phase 4 interventional study of Nux vomica (active comparator) and Placebo (placebo comparator) in Atrial Fibrillation, sponsored by Medical University of Vienna. Terminated at 1 site in Austria. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-08-16.
Sponsored by Medical University of Vienna · Phase 4, Interventional, and Treatment
After heart surgery, about 30% of patients suffer from atrial fibrillation. Patients are randomized into two groups receiving either potentized Strychnos Nux vomica or placebo under double blind conditions. Postoperatively, ECGs are done to monitor cardiac rhythm.
Preoperatively, patients receive potentized Nux vomica or placebo sublingually. Then, patients are observed regarding atrial fibrillation postsurgical. The difference between the group of patients with and without nux vomica is recorded.
3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.
This study's enrollment of 12 is below the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 179 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
Drug: Placebo (placebo comparator)
Patients receive Nux vomica globules made out of sugar sublingually before surgery.
Drug: Nux vomica (active comparator)
Patients receive Nux vomica in a homeopathic potentiation
Also known as: Strychnos Nux vomica C200
Patients receive Placebo looking similar to active drug
Also known as: Placebo globules
Frequency of atrial fibrillation after heart surgery with heart lung machine
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna